Bo Ma1, Qianqian Ma2, Chunhui Jin3, Xiaohong Wang4, Guolei Zhang4, Huiying Zhang4, Harald Seeger2, Alfred O Mueck2. 1. Affiliated Central Hospital of Huzhou Teachers College Huzhou, Zhejiang 313000, China ; University Hospital Tuebingen, Germany. 2. University Hospital Tuebingen, Germany. 3. Wuxi Hospital of Traditional Chinese Medicine China. 4. Affiliated Central Hospital of Huzhou Teachers College Huzhou, Zhejiang 313000, China.
Abstract
OBJECTIVES: Our study was aimed to make sure whether ADAM12 could serve as a prognostic biomarker of estrogen receptor (ER) -positive breast cancer. METHODS: 127 patients with ER-positive breast cancer were included in the present study. The level of ADAM12 was assayed through real-time quantitative PCR (RT-qPCR). Levels of ADAM12 in tumor tissues and adjacent normal tissues were compared with paired t-test. The association of ADAM12 expression with clinical characteristics was analyzed via χ(2) test. Kaplan-Meier survival curve was used to evaluate the role of ADAM12 expression in overall survival (OS) of patients. Cox-regression analysis was performed to judge if ADAM12 could serve as a prognostic marker in breast cancer. RESULTS: The level of ADAM12 was upregulated in tumor tissues of breast cancer compared to that of adjacent normal tissues (P < 0.05). The expression of ADAM12 was closely related to the Ki-67 and HER2 status (P < 0.05 for both). The results of Kaplan-Meier survival curve showed that patients with higher level of ADAM12 exhibited shorter survival time compared to that of low level of ADAM12 (P < 0.001). Cox regression analysis showed that ADAM12 might be a biomarker in predicting prognosis of patients with ER-positive breast cancer (HR = 7.116, 95% CI = 3.329-15.212). CONCLUSION: ADAM12 appears to be a prognostic marker in ER-positive breast cancer.
OBJECTIVES: Our study was aimed to make sure whether ADAM12 could serve as a prognostic biomarker of estrogen receptor (ER) -positive breast cancer. METHODS: 127 patients with ER-positive breast cancer were included in the present study. The level of ADAM12 was assayed through real-time quantitative PCR (RT-qPCR). Levels of ADAM12 in tumor tissues and adjacent normal tissues were compared with paired t-test. The association of ADAM12 expression with clinical characteristics was analyzed via χ(2) test. Kaplan-Meier survival curve was used to evaluate the role of ADAM12 expression in overall survival (OS) of patients. Cox-regression analysis was performed to judge if ADAM12 could serve as a prognostic marker in breast cancer. RESULTS: The level of ADAM12 was upregulated in tumor tissues of breast cancer compared to that of adjacent normal tissues (P < 0.05). The expression of ADAM12 was closely related to the Ki-67 and HER2 status (P < 0.05 for both). The results of Kaplan-Meier survival curve showed that patients with higher level of ADAM12 exhibited shorter survival time compared to that of low level of ADAM12 (P < 0.001). Cox regression analysis showed that ADAM12 might be a biomarker in predicting prognosis of patients with ER-positive breast cancer (HR = 7.116, 95% CI = 3.329-15.212). CONCLUSION:ADAM12 appears to be a prognostic marker in ER-positive breast cancer.
Entities:
Keywords:
ADAM12; breast cancer; clinical outcome; estrogen receptor
Authors: Chee Leong Cheng; Aye Aye Thike; Sie Yong Jane Tan; Pei Jou Chua; Boon Huat Bay; Puay Hoon Tan Journal: Breast Cancer Res Treat Date: 2015-04-14 Impact factor: 4.872
Authors: Camilla Fröhlich; Camilla Nehammer; Reidar Albrechtsen; Pauliina Kronqvist; Marie Kveiborg; Atsuko Sehara-Fujisawa; Arthur M Mercurio; Ulla M Wewer Journal: Mol Cancer Res Date: 2011-08-29 Impact factor: 5.852
Authors: Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu Journal: Science Date: 2006-09-07 Impact factor: 47.728
Authors: Uwe Lendeckel; Jana Kohl; Marco Arndt; Stacy Carl-McGrath; Hans Donat; Christoph Röcken Journal: J Cancer Res Clin Oncol Date: 2004-09-30 Impact factor: 4.553
Authors: Kristina P Sørensen; Mads Thomassen; Qihua Tan; Martin Bak; Søren Cold; Mark Burton; Martin J Larsen; Torben A Kruse Journal: Breast Cancer Res Date: 2015-04-11 Impact factor: 6.466
Authors: Tong Jiao; Ye Yao; Bo Zhang; Da-Cheng Hao; Qing-Feng Sun; Jing-Bo Li; Chao Yuan; Bao Jing; Yun-Peng Wang; Hai-Yang Wang Journal: Biomed Res Int Date: 2017-03-05 Impact factor: 3.411
Authors: Ashley S Cloud; Aditya M Vargheese; Sumedha Gunewardena; Raeann M Shimak; Sornakala Ganeshkumar; Easwari Kumaraswamy; Roy A Jensen; Vargheese M Chennathukuzhi Journal: BMC Cancer Date: 2022-02-17 Impact factor: 4.430
Authors: Sanne Ten Hoorn; Cynthia Waasdorp; Martijn G H van Oijen; Helene Damhofer; Anne Trinh; Lan Zhao; Lisanne J H Smits; Sanne Bootsma; Gabi W van Pelt; Wilma E Mesker; Linda Mol; Kaitlyn K H Goey; Miriam Koopman; Jan Paul Medema; Jurriaan B Tuynman; Inti Zlobec; Cornelis J A Punt; Louis Vermeulen; Maarten F Bijlsma Journal: BMC Cancer Date: 2022-04-12 Impact factor: 4.638